Compare Lionsgate Studios Corp Common Shares (LION) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs Sanofi SA — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.89 (market cap $3.24B), while Sanofi SA trades at $40.66 (market cap $96.38B). The key difference: Sanofi SA is far larger — about 29.7× Lionsgate Studios Corp Common Shares's market cap, and Sanofi SA pays a 6.08% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and Sanofi SA for 94 Days on average.
| LION | SNY | |
|---|---|---|
Market Cap | $3.24B | $96.38B |
Volume | 3,214,595 | 5,335,342 |
Sector | Technology | Health |
52-Week High | $16.40 | $52.34 |
52-Week Low | $5.91 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $6.75B | $115.67B |
Dividend Yield | — | 6.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
SNY trades at $39.12, down 1.56% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, potentially driving future growth. Analyst consensus is mixed, with 44% buy ratings but a majority hold stance.
The outlook is cautiously optimistic, supported by earnings beats and strategic partnerships, but risks include a projected net income decline in 2026 and competitive pressures. The stock's current valuation metrics, such as a P/E of 22.06, appear reasonable relative to historical performance, though investor sentiment remains tempered by near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
